SCHEMBL341352

SCHEMBL341352

CC(C(=O)O)c1cccc(-c2ccccc2)c1NC(=O)c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.50
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.49
MAPT P10636 2/20 0.45
HSP90AA1 P07900 2/20 0.45
HSP90AB1 P08238 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CXCL8 P10145 1/20 0.45
ADORA3 P0DMS8 3/20 0.44
ADORA2A P29274 1/20 0.44
HTT P42858 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 1/20 0.44
NOD2 Q9HC29 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 2/20 0.43
SERPINE1 P05121 1/20 0.43
APAF1 O14727 1/20 0.43
MITF O75030 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL339905 0.83 HSP90AA1 (0.35) LMNAKMT2AMEN1MAPTHSP90AA1
SCHEMBL16203451 0.80 LMNA (0.77) LMNAKMT2AMEN1HSP90AA1HSP90AB1
SCHEMBL339362 0.80 CXCL8 (0.46) LMNAKMT2AMEN1MAPTHSP90AA1
SCHEMBL341017 0.79 KMT2A (0.45) LMNAKMT2AMEN1MAPTNPC1
SCHEMBL338541 0.77 MAPT (0.43) KMT2AMEN1MAPTNPC1RAB9A
SCHEMBL341491 0.75 SOAT1 (0.46) LMNAKMT2AMEN1MAPTNPC1
SCHEMBL27710511 0.75 LMNA (0.63) LMNAKMT2AMEN1MAPTNPC1
SCHEMBL21480122 0.73 KMT2A (0.57) LMNAKMT2AMEN1HSP90AA1HSP90AB1
SCHEMBL6059859 0.73 KMT2A (0.64) LMNAKMT2AMEN1MAPTNPC1
SCHEMBL18061111 0.72 TAAR1 (0.51) LMNAKMT2AMEN1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181175-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2015-11-10 US disclosed
EP-2387558-B1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARM CO LTD (CN) 2014-08-27 EP disclosed
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2014-06-26 US disclosed
US-8703990-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2014-04-22 US disclosed
US-20120016151-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID NOVARTIS AG (CH) 2012-01-19 US disclosed
EP-2387558-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) 2011-11-23 EP disclosed
US-20110253230-A1 Temperature Sensitive Valve Having Shape Memory Actuator OMNITEK PARTNERS LLC (US) 2011-10-20 US disclosed
WO-2010081410-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2010-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID DNPEP, MME, DPP7 LMNA 1839/4885KMT2A 2149/4885MEN1 3083/4885
US-20120016151-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID DNPEP, MME, DPP7 LMNA 1839/4885KMT2A 2149/4885MEN1 3083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.